Graviti Pharms Company Profile
✉ Email this page to a colleague
What is the competitive landscape for GRAVITI PHARMS
GRAVITI PHARMS has seventeen approved drugs.
Summary for Graviti Pharms
| US Patents: | 0 |
| Tradenames: | 16 |
| Ingredients: | 16 |
| NDAs: | 17 |
Drugs and US Patents for Graviti Pharms
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Graviti Pharms | LOSARTAN POTASSIUM | losartan potassium | TABLET;ORAL | 219859-001 | Sep 19, 2025 | AB | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ||||
| Graviti Pharms | TRAZODONE HYDROCHLORIDE | trazodone hydrochloride | TABLET;ORAL | 217740-004 | Aug 27, 2024 | AB | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ||||
| Graviti Pharms | ESOMEPRAZOLE MAGNESIUM | esomeprazole magnesium | CAPSULE, DELAYED RELEASE;ORAL | 216349-001 | Jun 24, 2022 | OTC | No | No | ⤷ Start Trial | ⤷ Start Trial | |||||
| Graviti Pharms | SPIRONOLACTONE | spironolactone | TABLET;ORAL | 219494-003 | Jan 23, 2025 | AB | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
